🟢 90/100

This product looks safe

  • Contains proprietary blend — exact ingredient amounts not disclosed
  • 14% of ingredients have research evidence
B Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

ℹ️ Contains proprietary blend — exact ingredient amounts not disclosed

Label Data

1 Capsule(s) Serving Size
28 Servings
Other Combinations Product Type
14% Evidence Coverage

Supplement Facts — Evidence Check

25 mg (125% DV)
✅ 1.8× RDA — within safe limits 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 25mg UL 35mg
Proprietary Blend
250 mg
(3s,4s)-4-[(3,4-dimethoxyphenyl)methyl]-3-hydroxy-3-[[3-methoxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-phenyl]methyl]oxolan-2-one
(2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl] butane-1,4-diol;(2r,3r,4s,5s,6r)- 6-(hydroxymethyl)oxane-2,3,4,5-tetrol
(s)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-decanone
Phenethyl(e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Standardized Phytochemical Complex

Other Ingredients

Gelatin Microcrystalline Cellulose Magnesium Stearate Silicon Dioxide Hypromellose Polyvinylpyrrolidone Maltodextrin

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult Male (18-50 Years)

Product Information

📋 Directions for Use

Suggested Usage: take one (1) capsule daily, at the same time each day, or as directed by a qualified healthcare practitioner. For best results take four to eight (4-8) consecutive weeks (1-2 Cycles). Do not take this product longer than 8 consecutive weeks.A for (4) week break between cycles is recommended.

⚠️ Warnings & Precautions

Warnings: Consult with a licensed physician before using this product. Do not take this product if you have prostate hypertrophy, liver disease, kidney or heart disease, or are being treated for any medical condition.

This product should not be taken by women. In particular, those women who are pregnant, lactating or trying to become pregnant, should not take this product.

Do not take this product if you have been diagnosed with elevated cholesterol, prostate cancer, testicular cancer or breast cancer, or are under the age of 18.

Keep this product and all supplements out of the reach of children. Must be 18 years of age or older to purchase this product.

Additional Information

bpi

The Effect of Test Compound (3s,4s)-4-[(3,4-dimethoxyphenyl)methyl]-3-hydroxy-3-[[3-methoxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-phenyl]methyl]oxolan-2-one on the induction of Alkaline Phosphatase, an Estrogen-Inducible Marker Enzyme, in a Human Cell Model. The cells were treated with various concentrations of the test compound (with (image) or without (image)) Estradiol in an estrogen-free medium and the Alkaline Phosphate Level was measured. Each value is presented as the mean + S.E. National Institutes of Health, National Library of Medicine indexed study: Biosci Biotechnol Biochem, 70(11), 2783-2785,2006. Figures adapted from study finding.

Induction of Alkaline Phosphatase (AP) % 120 100 80 60 40 20 0 Shut Down Aromatase - Boost Up Free Testosterone 0 0.5 1.0 1.5 2.0 Concentration (ug/ml) Comparative Anti-Aromatase Activity in a Human Cell Model 0.43 ug/ml 0.31 ug/ml IC_ Values (Half Maximal Inhibitory Concentration) Potent Aromatase-Inhibition

This product has undergone extensive R&D, and has been tested by multiple globally-recognized independent 3rd party analytical and research laboratories.

Product Details

DSLD Entry Date 2012-08-24
Product Type Other Combinations
Form Capsule
Brand BPI
DSLD ID 12071
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →